{"entity":{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","aka":["Bozitinib","APL-101","CBT-101"],"tldr":"Vebreltinib is a Chinese MET inhibitor approved in 2023 for lung cancers with a MET exon 14 skipping mutation, and the first drug tested in a phase 3 trial for glioblastomas carrying a PTPRZ1-MET fusion.","summary":"Beijing Pearl Biotechnology's vebreltinib (PLB1001, also developed as APL-101 by Apollomics) was approved by China's NMPA in November 2023 for locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping. Because it crosses the blood-brain barrier, it was also taken into a randomised phase 3 trial in secondary glioblastoma with PTPRZ1-MET fusions, a rare molecular subgroup identified by Chinese neuro-oncology groups, and a further trial in MET-altered lung cancer is registered.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Vebreltinib","url":"https://clinicaltrials.gov/search?intr=PLB1001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","glioblastoma","sclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["met"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06105619","nct05989542"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"code":"PLB1001","modality":"Oral selective MET tyrosine kinase inhibitor","mechanism":"A selective, brain-penetrant inhibitor of the MET kinase; tumours with MET exon 14 skipping mutations, MET amplification or PTPRZ1-MET fusions depend on that signal.","approvals":[{"region":"CN","year":2023,"indication":"Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vebreltinib/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"trial":[{"id":"nct05989542","kind":"trial","name":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","route":"/trials/nct05989542/"},{"id":"nct06105619","kind":"trial","name":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","route":"/trials/nct06105619/"},{"id":"nct06930794","kind":"trial","name":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","route":"/trials/nct06930794/"},{"id":"nct03175224","kind":"trial","name":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","route":"/trials/nct03175224/"},{"id":"nct06574347","kind":"trial","name":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","route":"/trials/nct06574347/"},{"id":"nct06343064","kind":"trial","name":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","route":"/trials/nct06343064/"}]}}